PriceTargets.com logo

GSK - GSK Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 3 Buy Ratings
  • 0 Strong Buy Ratings
$40.50 As of 04/15/2024 01:00 AM ET
▼ -0.16 (-0.39%)

This chart shows the closing price for GSK by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New GSK Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GSK and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GSK

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 5 analysts offering 12 month price targets for GSK in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $40.50.

This chart shows the closing price for GSK for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in GSK. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/23/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/21/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
7/20/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
10/18/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
1/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
3/16/2024
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
4/15/2024

Latest Recommendations

  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2024GuggenheimUpgradeNeutral ➝ BuyLow
2/13/2024CitigroupUpgradeNeutral ➝ BuyLow
1/23/2024Morgan StanleyInitiated CoverageEqual WeightLow
1/3/2024Jefferies Financial GroupUpgradeHold ➝ BuyLow
7/14/2023HSBCInitiated CoverageReduceLow
3/17/2023Deutsche Bank AktiengesellschaftUpgradeHold ➝ BuyLow
2/26/2023The Goldman Sachs GroupInitiated CoverageBuy ➝ BuyLow
2/10/2023Berenberg BankBoost TargetGBX 1,580 ➝ GBX 1,730Low
2/2/2023JPMorgan Chase & Co.Boost TargetGBX 1,350 ➝ GBX 1,400Low
1/3/2023JPMorgan Chase & Co.DowngradeNeutral ➝ UnderweightLow
12/8/2022AlphaValueUpgradeBuyLow
12/5/2022Bank of AmericaDowngradeNeutral ➝ UnderperformN/A
12/2/2022CitigroupLower TargetGBX 1,975 ➝ GBX 1,550Low
11/30/2022Morgan StanleyLower TargetGBX 1,650 ➝ GBX 1,535Low
11/11/2022UBS GroupDowngradeNeutral ➝ SellLow
11/8/2022JPMorgan Chase & Co.Lower TargetGBX 1,900 ➝ GBX 1,600Low
10/14/2022BarclaysLower TargetGBX 1,800 ➝ GBX 1,450Low
10/12/2022Morgan StanleyBoost TargetGBX 1,550 ➝ GBX 1,650Low
9/29/2022Oddo BhfUpgradeNeutral ➝ OutperformLow
9/15/2022Credit Suisse GroupUpgradeUnderperform ➝ NeutralLow
9/8/2022Jefferies Financial GroupDowngradeBuy ➝ HoldLow
9/7/2022Deutsche Bank AktiengesellschaftLower TargetGBX 1,750 ➝ GBX 1,500Low
9/7/2022Morgan StanleyLower TargetGBX 1,860 ➝ GBX 1,550Low
8/5/2022Morgan StanleyReiterated RatingEqual WeightLow
7/21/2022CitigroupReiterated RatingNeutralLow
7/20/2022UBS GroupLower TargetGBX 1,876 ➝ GBX 1,850Low
7/19/2022AlphaValueDowngradeReduceLow
7/15/2022Credit Suisse GroupBoost TargetGBX 1,400 ➝ GBX 1,600Low
4/29/2022BarclaysBoost TargetGBX 1,775 ➝ GBX 1,800Low
4/28/2022JPMorgan Chase & Co.Boost TargetGBX 1,740 ➝ GBX 1,900Low
4/14/2022BarclaysBoost TargetGBX 1,675 ➝ GBX 1,775Low
2/28/2022Stifel NicolausInitiated CoverageHoldLow
2/11/2022DZ BankDowngradeBuy ➝ HoldLow
11/24/2021Berenberg BankReiterated RatingBuyMedium
11/8/2021UBS GroupReiterated RatingNeutralLow
11/5/2021BarclaysUpgradeUnderweight ➝ Equal WeightMedium
11/3/2021Morgan StanleyReiterated RatingEqual WeightLow
11/1/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/28/2021BarclaysReiterated RatingUnderweightLow
10/18/2021Berenberg BankReiterated RatingBuyLow
10/7/2021Morgan StanleyReiterated RatingEqual WeightLow
9/20/2021UBS GroupReiterated RatingNeutralLow
8/26/2021UBS GroupReiterated RatingNeutralLow
8/20/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
8/19/2021Berenberg BankReiterated RatingBuyLow
8/3/2021UBS GroupReiterated RatingNeutralLow
7/19/2021BarclaysReiterated RatingUnderweightMedium
7/6/2021Morgan StanleyReiterated RatingEqual WeightLow
7/1/2021UBS GroupReiterated RatingNeutralLow
6/24/2021Credit Suisse GroupReiterated RatingUnderperformLow
6/23/2021Deutsche Bank AktiengesellschaftUpgradeSell ➝ HoldLow
6/11/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
6/2/2021Baader BankReiterated RatingBuyLow
5/11/2021UBS GroupReiterated RatingNeutralLow
4/30/2021Deutsche Bank AktiengesellschaftReiterated RatingSellLow
4/20/2021Morgan StanleyReiterated RatingEqual WeightLow
4/20/2021UBS GroupReiterated RatingNeutralLow
3/29/2021SVB LeerinkReiterated RatingOutperform ➝ Market PerformN/A
3/23/2021SVB LeerinkDowngradeOutperform ➝ Market PerformLow
2/12/2021Morgan StanleyReiterated RatingEqual WeightLow
2/11/2021Berenberg BankReiterated RatingBuyLow
2/9/2021JPMorgan Chase & Co.Reiterated RatingNeutralLow
2/8/2021UBS GroupReiterated RatingNeutralLow
2/5/2021BarclaysReiterated RatingUnderweightLow
2/3/2021Deutsche Bank AktiengesellschaftDowngradeHold ➝ SellLow
1/20/2021UBS GroupReiterated RatingNeutralLow
1/20/2021Credit Suisse GroupDowngradeNeutral ➝ UnderperformLow
1/15/2021Deutsche Bank AktiengesellschaftInitiated CoverageHoldLow
12/16/2020DZ BankReiterated RatingBuyLow
12/8/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
12/3/2020UBS GroupDowngradeBuy ➝ NeutralLow
11/13/2020Morgan StanleyUpgradeUnderweight ➝ Equal WeightLow
11/2/2020Liberum CapitalUpgradeHold ➝ BuyLow
10/30/2020BarclaysReiterated RatingUnderweightLow
10/21/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
10/12/2020UBS GroupReiterated RatingBuyLow
10/9/2020Morgan StanleyReiterated RatingUnderweightLow
10/5/2020Credit Suisse GroupReiterated RatingNeutralLow
9/29/2020Berenberg BankInitiated CoverageBuyLow
9/23/2020Oddo BhfUpgradeNeutral ➝ BuyMedium
9/18/2020Societe GeneraleReiterated RatingBuyLow
9/8/2020JPMorgan Chase & Co.Reiterated RatingNeutralMedium
9/1/2020AlphaValueUpgradeBuyMedium
9/1/2020Morgan StanleyReiterated RatingUnderweightMedium
8/12/2020UBS GroupReiterated RatingBuyLow
5/14/2020UBS GroupReiterated RatingBuyLow
5/5/2020JPMorgan Chase & Co.Reiterated RatingNeutralLow
4/30/2020BarclaysReiterated RatingUnderweightLow
2/12/2020Shore CapitalDowngradeHold ➝ SellLow
1/16/2020BarclaysDowngradeEqual Weight ➝ UnderweightLow
12/2/2019SVB LeerinkInitiated CoverageOutperformLow
11/27/2019UBS GroupUpgradeNeutral ➝ BuyN/A
11/21/2019UBS GroupUpgradeNeutral ➝ BuyLow
10/16/2019New Street ResearchUpgradeReduce ➝ HoldLow
10/11/2019Cantor FitzgeraldUpgradeHold ➝ BuyMedium
9/3/2019Societe GeneraleUpgradeSell ➝ BuyLow
8/29/2019Jefferies Financial GroupReiterated RatingBuyLow
8/13/2019JPMorgan Chase & Co.Reiterated RatingNeutral ➝ NeutralLow
6/17/2019Morgan StanleyReiterated RatingUnderweight ➝ UnderweightLow
6/10/2019CowenReiterated RatingHold$45.00Low
(Data available from 4/16/2019 forward)

News Sentiment Rating

0.62 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 14 very positive mentions
  • 21 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Mentions as of
9/18/2023
  • 16 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
Mentions as of
10/18/2023
  • 6 very positive mentions
  • 17 positive mentions
  • 4 negative mentions
  • 6 very negative mentions
Mentions as of
11/17/2023
  • 19 very positive mentions
  • 6 positive mentions
  • 2 negative mentions
  • 6 very negative mentions
Mentions as of
12/17/2023
  • 14 very positive mentions
  • 21 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
Mentions as of
1/16/2024
  • 29 very positive mentions
  • 38 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
Mentions as of
2/15/2024
  • 34 very positive mentions
  • 24 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
Mentions as of
3/16/2024
  • 11 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 3 very negative mentions
Mentions as of
4/15/2024

Current Sentiment

  • 11 very positive mentions
  • 11 positive mentions
  • 2 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

GSK logo
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
Read More

Today's Range

Now: $40.50
Low: $40.44
High: $41.06

50 Day Range

MA: $42.07
Low: $40.50
High: $43.58

52 Week Range

Now: $40.50
Low: $33.33
High: $43.84

Volume

3,373,652 shs

Average Volume

3,538,386 shs

Market Capitalization

$83.93 billion

P/E Ratio

13.46

Dividend Yield

3.91%

Beta

0.64

Frequently Asked Questions

What sell-side analysts currently cover shares of GSK?

The following Wall Street sell-side analysts have issued reports on GSK in the last twelve months: Citigroup Inc., Guggenheim, HSBC Holdings plc, Jefferies Financial Group Inc., Morgan Stanley, and StockNews.com.
View the latest analyst ratings for GSK.

What is the current price target for GSK?

0 Wall Street analysts have set twelve-month price targets for GSK in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for GSK in the next year.
View the latest price targets for GSK.

What is the current consensus analyst rating for GSK?

GSK currently has 1 sell rating, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GSK, but not buy more shares or sell existing shares.
View the latest ratings for GSK.

What other companies compete with GSK?

Other companies that are similar to GSK include Zoetis, Regeneron Pharmaceuticals, Vertex Pharmaceuticals, Bristol-Myers Squibb and Sanofi. Learn More about companies similar to GSK.

How do I contact GSK's investor relations team?

GSK's physical mailing address is 980 GREAT WEST ROAD, BRENTFORD X0, TW8 9GS. The pharmaceutical company's listed phone number is 442080475000 and its investor relations email address is [email protected]. The official website for GSK is www.gsk.com. Learn More about contacing GSK investor relations.